

-- BACKGROUND OF THE INVENTION --

On page 2, between the second and third paragraph, please insert the following line:

-- SUMMARY OF THE INVENTION --

On page 2, before the last paragraph, please insert the following text:

-- BRIEF DESCRIPTION OF THE DRAWING

a' For a better understanding of the invention, reference is had to the following description taken in connection with the accompanying drawing.

The drawing is a cross-sectional view of an aerosol container constructed in accordance with the invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS --

nc On page 4, fourth line from the bottom, please delete "such containers" and insert --aerosol containers in accordance with the invention--.

IN THE CLAIMS

Please amend claims 1-3 and 5-8 and add new claims 9-14 as follows:

a' 2 1. (Once amended) An aerosol container for administering pharmaceutically active aerosols [that are to be administered in predetermined amounts and that are] supplied in the container in the form of a suspension, the suspension [also comprising, in addition to] including a pharmaceutically active [substance, at least] substance and a propellant gas,

[which] said aerosol container [has] comprising a metering valve [that comprises] having a metering chamber and a valve stem, the metering chamber being in communication with the interior of the container and being full [of a predetermined amount] of the aerosol in a first position of the valve stem, and releasing the amount of aerosol disposed in the metering chamber in a second position of the valve stem, wherein the propellant gas is an alternative propellant gas that is free of fluorochlorohydrocarbons, [preferably a propellant gas that comprises only fluorohydrocarbons and, where appropriate, also cosolvents and/or surfactants,] and wherein the inner wall of the container is coated with a plastics coating which inhibits the pharmaceutically active substance from depositing thereon.

*A2  
cancel*

2. (Once amended) An aerosol container according to claim 1, wherein the plastics coating [disposed on the inner wall of the container] is [of] polytetrafluoroethylene or perfluoroethylenepropylene.

*Pub  
C1*

3. (Once amended) An aerosol container according to claim 1, wherein the thickness of the container wall is in the range from approximately 0.1 mm to approximately 2 mm, [and is especially approximately 0.4 mm,] and the thickness of the plastics coating is in the range from approximately 1 nm to approximately 1 mm[, and is especially some 10 nm].

*Pub  
C1  
A3*

5. (Once amended) Method for the storage and administration [of a predetermined amount] of a pharmaceutically active aerosol in the form of a suspension, the suspension [also comprising, in addition to] including a pharmaceutically active [substance, at least] substance and an alternative propellant gas that is free of fluorochlorohydrocarbons, [preferably a propellant gas that comprises only fluorohydrocarbons and, where appropriate, also cosolvents and/or surfactants,] wherein a container according to claim 1 is used.

13 6. (Once amended) Method according to claim 5, wherein the pharmaceutically active <sup>agent</sup> ~~substance~~ in the suspension [used] is an anti-asthmatically active <sup>agent</sup> ~~substance~~ [or substance mixture].

14 7. (Once amended) Method according to claim 6, wherein the [pharmaceutically] ~~anti-asthmatically~~ active <sup>agent</sup> ~~substance~~ [in the suspension used is Formoterol or a corticosteroid, especially 9 $\alpha$ -chloro-6 $\alpha$ -fluoro-11 $\beta$ ,17 $\alpha$ -dihydroxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -methoxycarbonyl-17-propionate, or a mixture of Formoterol and that corticosteroid] is selected from the group consisting of formoterol, formoterol fumarate, and corticosteroids.

15 8. (Once amended) Method according to claim 6, wherein the [pharmaceutically] ~~anti-asthmatically~~ active <sup>agent</sup> ~~substance~~ [used] is (1R,2S)-(3E,5Z)-7-[1-(3-trifluoromethylphenyl)-1-hydroxy-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-3,5-decadien-2-ylthio]-4-oxo-4H-1-benzopyrane-2-carboxylic acid or the sodium salt thereof.

16 9. An aerosol container according to claim 1, wherein the propellant gas consists essentially of fluorohydrocarbons.

17 10. An aerosol container according to claim 1, wherein the suspension further includes cosolvents and/or surfactants.

18 11. An aerosol container according to claim 3, wherein the thickness of the container wall is approximately 0.4 mm and the thickness of the plastics coating is approximately 10 nm.

19 12. Method according to claim 5, wherein the propellant gas consists essentially of fluorohydrocarbons.